COMMUNIQUÉS West-GlobeNewswire

Athenex, Inc. Receives U.S. FDA Orphan Drug Designation for Oraxol for the Treatment of Angiosarcoma
19/04/2018
BUFFALO, N.Y., April 19, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
ICC Labs Enters Into Letter of Intent With Eurofarma Uruguay S.A., a Member of the Brazilian-Owned Multinational Eurofarma Group of Pharmaceutical Companies
19/04/2018
VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- ICC Labs Inc. (“ICC Labs” or the “Company”) (TSX-V: ICC ) (Frankfurt: 2Q9 ) is pleased to announce that one of its Uruguayan subsidiaries has entered into [...]
Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial
19/04/2018
Summit Therapeutics plc ("Summit" or the "Company") Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial Top-line Data On Track to be Reported During Q3 2018 Oxford, UK, and Cambridge, MA, US, 19 April [...]
Tetraphase Pharmaceuticals to Present Data at the 38th Annual Meeting of the Surgical Infection Society
19/04/2018
WATERTOWN, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH ), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening [...]
EyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
19/04/2018
Conference Call Scheduled for 4:30 p.m. ET on Tuesday, May 8th WATERTOWN, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT ) (ASX:PVA), a specialty biopharmaceutical company [...]
NeuroMetrix Reports Q1 2018 Financial Results
19/04/2018
GlaxoSmithKline Collaboration is Quarter Highlight WALTHAM, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO ), today reported financial and business highlights for the quarter ended March 31, [...]
Axsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial Officer
19/04/2018
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM ), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders [...]
miRagen Therapeutics to Present New Preclinical Data at the Wound Healing Society and the Association for Research in Vision and Ophthalmology Annual Meetings
19/04/2018
BOULDER, Colo., April 19, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN ), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced [...]
Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
19/04/2018
Findings are the Basis for the HOPE-2 Clinical Trial LOS ANGELES, April 19, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR ) today announced that researchers found that repeat dosing of the company’s [...]
Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018
19/04/2018
Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS ), a clinical-stage immuno-oncology company developing [...]
XORTX Announces PKD Foundation Collaboration
19/04/2018
CALGARY, Alberta, April 19, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX) is pleased to announce that the PKD Foundation has recognized XORTX as a leader in advancing the [...]
Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial
19/04/2018
Top-line Data On-track to be Reported During Q3 2018 OXFORD, United Kingdom and CAMBRIDGE, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT ) (AIM:SUMM) announces the completion of [...]
Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018
19/04/2018
GAITHERSBURG, Md., April 19, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) will host a conference call on Thursday, May 3, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the first [...]
This Week in the News: A Curated Selection of the Best Media Coverage on PotNetwork Holdings, Inc.
19/04/2018
PotNetwork Holdings, Inc. featured in International Business Times, Small Cap Network, Born2Invest, Natural Way & Ultra Meds Global FT LAUDERDALE, Fla., April 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- [...]
Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
19/04/2018
-- Patients receiving GOCOVRI experienced long-term durability for up to two years -- -- Safety profile was consistent with previously-published controlled Phase 3 studies -- EMERYVILLE, Calif., April 19, 2018 (GLOBE [...]
Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 26,000,000
19/04/2018
Uppsala, Sweden April 19, 2018 – Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 26,000,000 with [...]
Motif Bio Announces New Iclaprim Data being Presented at ECCMID 2018
19/04/2018
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Positive efficacy and safety highlights from Phase 3 REVIVE-2 trial in ABSSSI Potential to avoid costs related to vancomycin-associated acute kidney injury in ABSSSI Data [...]
Herantis Pharma awarded Innovation prize of the Chemical Industry Federation of Finland
19/04/2018
Herantis Pharma awarded Innovation prize of the Chemical Industry Federation of Finland Herantis Pharma Plc Press release 19 Apr 2018 at 8:30 am The Innovation prize 2018 of Finland's Chemical Industry Federation was [...]
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
19/04/2018
Basel, April 19, 2018 - Novartis announced today the appointment of John Tsai, M.D. as Head of Global Drug Development (GDD) and Chief Medical Officer. Dr. Tsai will join Novartis on May 1, 2018, and will be based in [...]

Pages